OKYO Pharma's Urcosimod Shows Quality-of-Life Gains in Neuropathic Corneal Pain Trial
Event summary
- OKYO Pharma reported new Phase 2a trial data showing urcosimod improved patient-reported quality of life in neuropathic corneal pain (NCP) patients.
- Patients on urcosimod reported greater improvements in emotional well-being and daily life satisfaction compared to placebo.
- The trial involved 12 weeks of treatment with 6 patients receiving urcosimod and 6 receiving placebo.
- Results will be presented at the ARVO 2026 Annual Meeting, highlighting pain reduction and potential corneal nerve restoration.
The big picture
OKYO Pharma's Phase 2a data for urcosimod in neuropathic corneal pain underscores the growing focus on patient-reported outcomes in clinical trials. The results highlight the potential for urcosimod to address a significant unmet medical need in ophthalmology, where chronic pain conditions like NCP currently lack FDA-approved therapies. The company's planned Phase 2b/3 trial will be critical in validating these findings and determining the drug's long-term viability in a market hungry for innovative pain management solutions.
What we're watching
- Clinical Validation
- Whether the exploratory quality-of-life benefits observed in Phase 2a will be confirmed in larger, multi-center Phase 2b/3 trials.
- Regulatory Pathway
- The pace at which OKYO Pharma advances urcosimod through regulatory approvals, given the lack of FDA-approved treatments for NCP.
- Market Differentiation
- How urcosimod's holistic therapeutic profile—beyond pain reduction—positions it in the competitive landscape of ophthalmic treatments.
Related topics